gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FLGTHealthcareMedical Labs

Fulgent Genetics, Inc. Common Stock (FLGT)

$19.86+2.50%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$19.37▼ 16.18% in range
Nov 3, 2025Low $13.79 · High $30.85Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Fulgent Genetics closed at $19.86 on Nov 4, up 2.50%, 35.6% below its 52-week closing high. Volume of 121.0K shares was 0.45× its 20-day average (below normal).

Split-adjusted performance: -3.5% over one month, +33.1% over six months, -14.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $85.39M, up 4.4% from a year earlier, with a net margin of -34.6%.

Short interest was 2.1M shares at the Oct 15 settlement, down 4.7% from the prior report (12.0% of float, 7.4 days to cover).

Market cap$546.3M27.5M shares
Revenue · quarter$85.4M+4.4% YoY
Diluted EPS$-1.05—
P/E · TTM—P/S 1.7×
Net margin-34.6%Gross 30.1%
Dividend yieldNone
52-week range13.79 – 30.85−35.6% from high
Volume121.0K0.45× 20-day avg
Volatility · 60d41.3%Annualised
Short % of float12.0%7.4 days to cover
Net cash$256.6MCash $257.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.7%1M −3.5%3M +7.0%6M +33.1%YTD −24.4%1Y −14.1%3Y −16.0%5Y −76.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum36
Revenue growth11
Net margin29
Value (low P/E)—
Size30

Industry medians: 6-month return +36.5%, revenue growth +25.0%, net margin −4.0%, P/E 32.5×.

Short interest

Details →
Shares short2.1M−4.7% vs prior
Days to cover7.4Settled Oct 15
% of float12.0%
Short vol. 10d45.2%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FLGTFulgent Genetics$19.86+2.50%+33.1%+4.4%−34.6%—$546.3M
CSTLCastle Biosciences$35.94+2.28%+45.2%+20.1%−2.0%—$1.10BCompare
FRNMFreenome$11.23−2.09%————$1.21BCompare
LMRILumexa Imaging Holdings$12.68+13.01%+23.3%—1.0%—$1.22BCompare
BDSXBiodesix$21.44+1.85%+42.9%+34.2%−27.1%—$226.2MCompare
XGNExagen$8.53+2.30%+176.1%+15.9%−16.0%—$206.7MCompare
PSNLPersonalis$15.76+0.06%+159.6%+30.0%−141.7%—$1.68BCompare
FTREFortrea Holdings$20.87−0.37%+33.5%−1.4%0.1%—$2.01BCompare
CELCCelcuity$68.72−1.43%−50.7%———$3.36BCompare

News about Fulgent Genetics

All news →
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?Zacks Investment Research · Sep 22, 2026▲ PositiveLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmGlobeNewswire Inc. · Apr 17, 2026▼ NegativeFLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsGlobeNewswire Inc. · Mar 20, 2026▼ Negative

Quick answers

What does Fulgent Genetics do?
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business.
What is FLGT's market cap?
$546.32M, based on the Nov 4 close of $19.86.
Does Fulgent Genetics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FLGT is sold short?
2.1M shares, 12.0% of float, as of Oct 15, 2026.
What sector is FLGT in?
Healthcare, in the Medical Labs industry.

About Fulgent Genetics

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

HQ: El Monte, CA1,315 employeesListed Sep 29, 2016fulgentgenetics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology